Review of recent studies on resistance to cytotoxic deoxynucleoside analogues.

[1]  K. Murai,et al.  Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. , 2007, Leukemia research.

[2]  K. Walldén,et al.  Crystal Structure of Human Cytosolic 5′-Nucleotidase II , 2007, Journal of Biological Chemistry.

[3]  Lijie Sun,et al.  Residues 334 and 338 in Transmembrane Segment 8 of Human Equilibrative Nucleoside Transporter 1 Are Important Determinants of Inhibitor Sensitivity, Protein Folding, and Catalytic Turnover* , 2007, Journal of Biological Chemistry.

[4]  Takashi Ishikawa,et al.  Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. , 2007, Oncology reports.

[5]  S. Ng,et al.  Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. , 2007, Cancer research.

[6]  G. Peters,et al.  In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs. , 2007, Journal of medicinal chemistry.

[7]  Y. Lee,et al.  RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo , 2007, Anti-cancer drugs.

[8]  Elisa Giovannetti,et al.  Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. , 2007, Pharmacological research.

[9]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[10]  Mark E. Davis,et al.  Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo , 2007, Clinical Cancer Research.

[11]  J. Cortes,et al.  Evaluation of the l-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia , 2007, Expert opinion on investigational drugs.

[12]  G. Moreno-Bueno,et al.  Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance , 2007, Breast Cancer Research and Treatment.

[13]  Y. Takeda,et al.  Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer , 2007, International journal of cancer.

[14]  M. Duxbury,et al.  RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. , 2007, Biochemical and biophysical research communications.

[15]  E. Hahn,et al.  bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells , 2007, Journal of cellular and molecular medicine.

[16]  Z. Kazimierczuk,et al.  Two novel nucleoside ester derivatives of chlorambucil as potential antileukemic prodrugs: a preliminary study , 2007, Anti-cancer drugs.

[17]  H. Iwasaki,et al.  Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells , 2007, International journal of hematology.

[18]  S. Han,et al.  Cloning and characterization of an alternative splicing transcript of the gene coding for human cytidine deaminase. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[19]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[20]  M. L. Beau,et al.  A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia , 2007, Leukemia.

[21]  M. Ishikawa,et al.  Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[22]  Hyo-Kyung Han,et al.  Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C , 2007, Acta Pharmacologica Sinica.

[23]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[24]  T. Okumura,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.

[25]  M. Erion,et al.  Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma , 2006 .

[26]  S. Burley,et al.  Structural basis for activation of the therapeutic l-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase , 2006, Nucleic acids research.

[27]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  T. Szekeres,et al.  5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. , 2006, Differentiation; research in biological diversity.

[29]  L. Klein-Hitpass,et al.  Differential Expression of Drug Resistance-Related Genes between Sensitive and Resistant Blasts in Acute Myeloid Leukemia , 2006, Acta Haematologica.

[30]  S. Seeber,et al.  Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. , 2006, Blood.

[31]  L. Cattel,et al.  Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. , 2006, Molecular pharmaceutics.

[32]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Couvreur,et al.  Squalenoyl nanomedicines as potential therapeutics. , 2006, Nano letters.

[34]  P. Bonate,et al.  Discovery and development of clofarabine: a nucleoside analogue for treating cancer , 2006, Nature Reviews Drug Discovery.

[35]  M. Vodnala,et al.  Enzymatically Active Mammalian Ribonucleotide Reductase Exists Primarily as an α6β2 Octamer* , 2006, Journal of Biological Chemistry.

[36]  K. Giacomini,et al.  Molecular Determinants of Specificity for Synthetic Nucleoside Analogs in the Concentrative Nucleoside Transporter, CNT2* , 2006, Journal of Biological Chemistry.

[37]  G. Bonn,et al.  Multicapillary electrophoresis analysis of single-nucleotide sequence variations in the deoxycytidine kinase gene. , 2006, Clinical chemistry.

[38]  Hyo-Kyung Han,et al.  Enhanced cellular uptake of Ara‐C via a peptidomimetic prodrug, L‐valyl‐ara‐C in Caco‐2 cells , 2006, The Journal of pharmacy and pharmacology.

[39]  R. Ueda,et al.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.

[40]  G. Bepler,et al.  Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. , 2006, Cancer research.

[41]  H. Spencer,et al.  Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection , 2006, Cancer Chemotherapy and Pharmacology.

[42]  J. Schellens,et al.  Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers , 2006, European Journal of Clinical Pharmacology.

[43]  J. Beckwith,et al.  Ribonucleotide reductases: influence of environment on synthesis and activity. , 2006, Antioxidants & redox signaling.

[44]  Hyun Cheol Chung,et al.  Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines , 2006, Pharmacogenetics and genomics.

[45]  S. Lowe,et al.  Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. , 2006, Experimental hematology.

[46]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  C. Leung,et al.  Apurinic/Apyrimidinic Endonuclease-1 Protein Level Is Associated with the Cytotoxicity of l-Configuration Deoxycytidine Analogs (Troxacitabine and β-l-2′,3′-Dideoxy-2′,3′-didehydro-5-fluorocytidine) but Not d-Configuration Deoxycytidine Analogs (Gemcitabine and β-d-Arabinofuranosylcytosine) , 2006, Molecular Pharmacology.

[48]  R. Ferrell,et al.  Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1 , 2006, Pharmacogenetics and genomics.

[49]  Y. Yen,et al.  Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. , 2006, Oncology reports.

[50]  C. Iacobuzio-Donahue,et al.  Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival , 2006, Clinical Cancer Research.

[51]  C. Galmarini,et al.  F-ara-AMP is a substrate of cytoplasmic 5′-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation , 2006, Nucleosides, nucleotides & nucleic acids.

[52]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[53]  R. Weinshilboum,et al.  Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics , 2006, Clinical Cancer Research.

[54]  G. Juliusson,et al.  The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. , 2006, Biochemical pharmacology.

[55]  T. Szekeres,et al.  Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC , 2006, Apoptosis.

[56]  A. Wunderlich,et al.  Antisense p53 oligonucleotides inhibit proliferation and induce chemosensitivity in follicular thyroid cancer cells. , 2006, Anticancer research.

[57]  C. Galmarini,et al.  Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells , 2006, Cancer Chemotherapy and Pharmacology.

[58]  G. Amidon,et al.  Nucleoside Ester Prodrug Substrate Specificity of Liver Carboxylesterase , 2006, Journal of Pharmacology and Experimental Therapeutics.

[59]  S. Ealick,et al.  The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. , 2006, Acta crystallographica. Section D, Biological crystallography.

[60]  A. Zanella,et al.  Hereditary erythrocyte pyrimidine 5′-nucleotidase deficiency: A biochemical, genetic and clinical overview , 2006, Hematology.

[61]  Y. Lee,et al.  GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. , 2006, International journal of oncology.

[62]  R. Ferrell,et al.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter , 2006, Human Genetics.

[63]  C. Cass,et al.  Studies of nucleoside transporters using novel autofluorescent nucleoside probes. , 2006, Biochemistry.

[64]  H. Ueno,et al.  Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Konrad,et al.  Structural basis for the preference of UTP over ATP in human deoxycytidine kinase: illuminating the role of main-chain reorganization. , 2006, Biochemistry.

[66]  Conrad C. Huang,et al.  FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2 , 2006, Drug Metabolism and Disposition.

[67]  P. Chien,et al.  In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate , 2006, Anti-cancer drugs.

[68]  U Creutzig,et al.  The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia , 2005, British Journal of Cancer.

[69]  Wei Guo,et al.  Activation of c‐Jun NH2‐terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells , 2005, FEBS letters.

[70]  S. Seeber,et al.  Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells , 2005, Leukemia.

[71]  G. Peters,et al.  Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. , 2005, Cancer Research.

[72]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[73]  A. Dueñas-González,et al.  Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives , 2005, Anti-cancer drugs.

[74]  J. Mackey,et al.  cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. , 2005, Lung cancer.

[75]  C. Galmarini,et al.  Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells , 2005, Molecular Cancer Therapeutics.

[76]  C. Cass,et al.  Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. , 2005, Biochemical pharmacology.

[77]  T. Szekeres,et al.  Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. , 2005, Leukemia research.

[78]  B. Mitchell,et al.  The 5'-nucleotidases as regulators of nucleotide and drug metabolism. , 2005, Pharmacology & therapeutics.

[79]  E. Giovannetti,et al.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma , 2005, British Journal of Cancer.

[80]  G. Peters,et al.  Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours , 2005, Journal of Clinical Pathology.

[81]  C. Dumontet,et al.  Regulation and activity of cytosolic 5′‐nucleotidase II , 2005, FEBS letters.

[82]  O. Stoeltzing,et al.  Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells , 2005, British Journal of Cancer.

[83]  R. Schilsky,et al.  A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  A. Fujioka,et al.  Possible antitumor activity of 1‐(3‐C‐ethynyl‐β‐d‐ribo‐pentofuranosyl)cytosine (ECyd, TAS‐106) against an established gemcitabine (dFdCyd)‐resistant human pancreatic cancer cell line , 2005, Cancer science.

[85]  N. Lemoine,et al.  Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in Pancreatic Cancer , 2005, Clinical Cancer Research.

[86]  C. Cass,et al.  Residue 33 of Human Equilibrative Nucleoside Transporter 2 Is a Functionally Important Component of Both the Dipyridamole and Nucleoside Binding Sites , 2005, Molecular Pharmacology.

[87]  H. Ueno,et al.  Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin , 2005, Clinical Cancer Research.

[88]  Y. Ravindranath,et al.  Role of USF1 in the differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia , 2005, Leukemia.

[89]  B. Greene,et al.  A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms , 2005, Cancer Chemotherapy and Pharmacology.

[90]  B. Vig,et al.  Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. , 2005, Molecular pharmaceutics.

[91]  C. Cass,et al.  Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene , 2005, Pharmacogenetics and genomics.

[92]  C. Endres,et al.  Residues Met89 and Ser160 in the Human Equilibrative Nucleoside Transporter 1 Affect Its Affinity for Adenosine, Guanosine, S6-(4-Nitrobenzyl)-mercaptopurine Riboside, and Dipyridamole , 2005, Molecular Pharmacology.

[93]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[94]  E. Guillén-Gómez,et al.  The concentrative nucleoside transporter family (SLC28): new roles beyond salvage? , 2005, Biochemical Society transactions.

[95]  Conrad C. Huang,et al.  Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 , 2005, Pharmacogenetics and genomics.

[96]  J. Martinez-Picado,et al.  Cell entry and export of nucleoside analogues. , 2005, Virus research.

[97]  J. Mackey,et al.  Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. , 2005, Blood.

[98]  G. Peters,et al.  Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts , 2004, Nucleosides, nucleotides & nucleic acids.

[99]  B. Dörken,et al.  Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway , 2004, Oncogene.

[100]  Silvia Arpicco,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[101]  Jiong Hu,et al.  Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. , 2004, Pharmacogenetics.

[102]  S. Katsuma,et al.  Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. , 2004, Journal of biochemistry.

[103]  H. Hori,et al.  Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. , 2004, Oncology reports.

[104]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[105]  G. Peters,et al.  Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity. , 2004, Cancer letters.

[106]  Ryuzo Ueda,et al.  Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer , 2004, Cancer science.

[107]  J. Mackey,et al.  Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line , 2004, Clinical Cancer Research.

[108]  S. Ashley,et al.  Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. , 2004, Surgery.

[109]  T. Szekeres,et al.  In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. , 2004, International journal of oncology.

[110]  R. Christopherson,et al.  Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. , 2004, Leukemia research.

[111]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[112]  S. Ashley,et al.  A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells , 2004, Cancer Research.

[113]  J. Mackey,et al.  Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene , 2004, BMC pharmacology.

[114]  Alan Cantor,et al.  RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  C. Endres,et al.  Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. , 2004, The Biochemical journal.

[116]  Lijun Xue,et al.  Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. , 2004, Biochemical pharmacology.

[117]  Conrad C. Huang,et al.  Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. , 2004, Molecular pharmacology.

[118]  R. Borch,et al.  Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. , 2004, Molecular pharmaceutics.

[119]  D. Colomer,et al.  Nucleoside transporters in chronic lymphocytic leukaemia , 2004, Leukemia.

[120]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[121]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[122]  G. Peters,et al.  Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. , 2004, Biochemical pharmacology.

[123]  S. Yao,et al.  The equilibrative nucleoside transporter family, SLC29 , 2004, Pflügers Archiv.

[124]  D. Sengupta,et al.  Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. , 2004, Biochemical pharmacology.

[125]  H. Gourdeau,et al.  Action of Troxacitabine on Cells Transduced with Human Cytidine Deaminase cDNA , 2004, Cancer investigation.

[126]  J. Taub,et al.  Physical and Functional Interactions between USF and Sp1 Proteins Regulate Human Deoxycytidine Kinase Promoter Activity* , 2003, Journal of Biological Chemistry.

[127]  W. Plunkett,et al.  Mechanisms of apoptosis induction by nucleoside analogs , 2003, Oncogene.

[128]  V. Bianchi,et al.  Mammalian 5′-Nucleotidases* , 2003, Journal of Biological Chemistry.

[129]  S. Ashley,et al.  RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. , 2003, Biochemical and biophysical research communications.

[130]  A. Karlsson,et al.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases , 2003, Pharmacology & Therapeutics.

[131]  J. Mackey,et al.  Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy† , 2003, Oncogene.

[132]  J. Mackey,et al.  Sensitization of ara‐C‐resistant lymphoma cells by a pronucleotide analogue , 2003, International journal of cancer.

[133]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  M. Cao,et al.  Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[135]  P. Reichard,et al.  Origins of mitochondrial thymidine triphosphate: Dynamic relations to cytosolic pools , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[136]  G. Kucera,et al.  Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside. , 2003, Journal of medicinal chemistry.

[137]  J. Balzarini,et al.  Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. , 2003, Biochemical pharmacology.

[138]  C. Dumontet,et al.  Drug resistance to cytotoxic nucleoside analogues. , 2003, Current drug targets.

[139]  Xuemei H. Chen,et al.  Synthesis of 5'-amino-5'-phosphonate analogues of pyrimidine nucleoside monophosphates. , 2003, The Journal of organic chemistry.

[140]  C. Monnerjahn,et al.  Structure of human dCK suggests strategies to improve anticancer and antiviral therapy , 2003, Nature Structural Biology.

[141]  C. Galmarini,et al.  Role of IMP-SELECTIVE 5′-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES , 2003, Leukemia & lymphoma.

[142]  A. Karlsson,et al.  Active site mutants of Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. , 2003, European journal of biochemistry.

[143]  J. Mackey,et al.  Deoxycytidine kinase and cN‐II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine , 2003, British journal of haematology.

[144]  S. Grant,et al.  Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. , 2003, Biochemical pharmacology.

[145]  V. Lam,et al.  GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. , 2003, Cancer research.

[146]  Conrad C. Huang,et al.  Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. , 2003, Pharmacogenetics.

[147]  Takuma Sasaki,et al.  The molecular targets of antitumor 2'-deoxycytidine analogues. , 2003, Current drug targets.

[148]  J. Wijnholds,et al.  Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. , 2003, Molecular pharmacology.

[149]  R. Willemze,et al.  Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. , 2003, Leukemia research.

[150]  Conrad C. Huang,et al.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[151]  G. Bepler,et al.  RRM1-induced metastasis suppression through PTEN-regulated pathways , 2003, Oncogene.

[152]  L. Pradayrol,et al.  Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[153]  H. Munier-Lehmann,et al.  Reaction of human UMP-CMP kinase with natural and analog substrates. , 2003, European journal of biochemistry.

[154]  E. Montserrat,et al.  Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. , 2003, Blood.

[155]  G. Peters,et al.  Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. , 2003, European journal of cancer.

[156]  D. Steinbach,et al.  Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[157]  S. Eriksson,et al.  Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. , 2003, Biochemical pharmacology.

[158]  R. Hohl,et al.  Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside. , 2002, The Journal of organic chemistry.

[159]  J. Wijnholds,et al.  Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. , 2002, Molecular pharmacology.

[160]  L. Chan,et al.  Novel nucleotide phosphonate analogues with potent antitumor activity. , 2002, Bioorganic & medicinal chemistry letters.

[161]  K. Johansson,et al.  Structure and function of cellular deoxyribonucleoside kinases , 2002, Cellular and Molecular Life Sciences CMLS.

[162]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[163]  C. Galmarini,et al.  Potential mechanisms of resistance to cytarabine in AML patients. , 2002, Leukemia research.

[164]  W. Lam,et al.  Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. , 2002, Cancer research.

[165]  Wing Lam,et al.  Phosphorylation of Pyrimidine Deoxynucleoside Analog Diphosphates , 2002, The Journal of Biological Chemistry.

[166]  P. Lum,et al.  A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. , 2002, Biochemistry.

[167]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[168]  C. Cass,et al.  Mutation of Residue 33 of Human Equilibrative Nucleoside Transporters 1 and 2 Alters Sensitivity to Inhibition of Transport by Dilazep and Dipyridamole* , 2002, The Journal of Biological Chemistry.

[169]  A. Karlsson,et al.  Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. , 2001, Biochemical and biophysical research communications.

[170]  C. Cass,et al.  Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. , 2001, Molecular pharmacology.

[171]  A. Karlsson,et al.  Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria. , 2001, Biochemical and biophysical research communications.

[172]  C. Cass,et al.  Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. , 2001, Cancer research.

[173]  J. Mackey,et al.  Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. , 2001, Blood.

[174]  Zhe-Sheng Chen,et al.  Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. , 2001, The Journal of biological chemistry.

[175]  A. Karlsson,et al.  Bystander effects of cancer cell lines transduced with the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster and synergistic enhancement by hydroxyurea. , 2001, Molecular pharmacology.

[176]  H. Eklund,et al.  Structural basis for substrate specificities of cellular deoxyribonucleoside kinases , 2001, Nature Structural Biology.

[177]  A. Karlsson,et al.  Retroviral Transduction of Cancer Cell Lines with the Gene Encoding Drosophila melanogaster Multisubstrate Deoxyribonucleoside Kinase* , 2000, The Journal of Biological Chemistry.

[178]  C. Wagner,et al.  Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides , 2000, Medicinal research reviews.

[179]  K. Jung,et al.  Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. , 2000, Bioorganic & medicinal chemistry.

[180]  J. Piškur,et al.  Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster. , 2000, Journal of molecular biology.

[181]  F. Baas,et al.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[182]  S. Eriksson,et al.  Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[183]  A. Karlsson,et al.  Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. , 1999, Molecular pharmacology.

[184]  E. De Clercq,et al.  Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. , 1999, Cancer research.

[185]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[186]  R. Christopherson,et al.  Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines. , 1998, The international journal of biochemistry & cell biology.

[187]  S. Seeber,et al.  Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. , 1998, Experimental hematology.

[188]  Yun Yen,et al.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential , 1998, Clinical & Experimental Metastasis.

[189]  J. Wright,et al.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[190]  J. Wright,et al.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[191]  B. Mitchell,et al.  Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. , 1996, Cancer research.

[192]  B. Mitchell,et al.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. , 1995, The Journal of clinical investigation.

[193]  T. Szekeres,et al.  In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. , 2007, Neoplasma.

[194]  Lijun Xue,et al.  Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. , 2007, Clinical colorectal cancer.

[195]  J. Balzarini,et al.  Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants , 2007, Gene Therapy.

[196]  L. Cattel,et al.  Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. , 2007, Anticancer research.

[197]  Dolors Colomer,et al.  Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. , 2006, Haematologica.

[198]  H. Ueno,et al.  Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). , 2006, Drug metabolism and pharmacokinetics.

[199]  E. Montserrat,et al.  Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells , 2005, Leukemia.

[200]  E. Burchard,et al.  Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) , 2005, The Pharmacogenomics Journal.

[201]  Y. Lai,et al.  Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. , 2005, American journal of physiology. Cell physiology.

[202]  H. Caron,et al.  Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma , 2005, Cancer Chemotherapy and Pharmacology.

[203]  C. Galmarini,et al.  The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. , 2005, Haematologica.

[204]  H. K. Erdemli,et al.  Pyrimidine 5'nucleotidase I and II activities in acute leukaemias. , 2004, Acta medica.

[205]  J. Mackey,et al.  5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. , 2004, Haematologica.

[206]  H. McLeod,et al.  Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway , 2004, The Pharmacogenomics Journal.

[207]  G. Peters,et al.  Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. , 2003, International journal of oncology.

[208]  K. Ota,et al.  A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. , 2003, Pharmacogenetics.